Gulácsy Vera, Maródi László
Debreceni Egyetem, Orvos- és Egészségtudományi Centrum, Infektológiai és Gyermekimmunológiai Tanszék, Debrecen, Nagyerdei krt. 98., Pf. 73, 4032.
Orv Hetil. 2011 Jan 9;152(2):64-7. doi: 10.1556/OH.2011.28940.
Patients with combined primary immunodeficiency or B-cell deficiency with low serum concentration of immunoglobulin G can be efficiently treated with immunoglobulin G concentrates. From the 1950s IgG was used intramuscularly, and from the 1980s intravenous immunoglobulin (IVIG) replacement has become widely available for replacement therapy. Among the potential side effects of IVIG (including anaphylaxis), further disadvantages of IVIG are hospitalization during treatment and varying concentrations of IgG. Over the past ten years, subcutaneous IgG (SCIG) preparations have become reasonable alternatives to IVIG. SCIG given weekly assures a more balanced serum IgG level, side affects are mostly local and temporary; systemic, severe adverse events have not been observed. In addition, SCIG can be used for home treatment of patients which improves their quality of life remarkably.
患有联合原发性免疫缺陷或B细胞缺陷且血清免疫球蛋白G浓度低的患者可用免疫球蛋白G浓缩物有效治疗。从20世纪50年代起，免疫球蛋白G通过肌肉注射使用，从20世纪80年代起，静脉注射免疫球蛋白（IVIG）替代疗法已广泛用于替代治疗。在IVIG的潜在副作用（包括过敏反应）中，IVIG的进一步缺点是治疗期间需要住院以及免疫球蛋白G浓度不同。在过去十年中，皮下注射免疫球蛋白（SCIG）制剂已成为IVIG的合理替代方案。每周注射SCIG可确保血清免疫球蛋白G水平更加平衡，副作用大多是局部的且是暂时的；尚未观察到全身性严重不良事件。此外，SCIG可用于患者的家庭治疗，这显著提高了他们的生活质量。
